, Volume 39, Issue 2, pp 209-219,
Open Access This content is freely available online to anyone, anywhere at any time.
Date: 05 Jan 2012

Aβ Imaging: feasible, pertinent, and vital to progress in Alzheimer’s disease

This is an excerpt from the content

The editorial by Moghbel and colleagues published in this issue of the European Journal of Nuclear Medicine and Molecular Imaging raises a number of concerns with regard to amyloid-beta (Aβ) imaging [1]. We appreciate the opportunity to address and clarify these concerns by referring to the scientific literature. There are several issues raised by Moghbel and colleagues which we acknowledge require careful consideration, further discussion, and research, including nonspecific white matter retention, the diagnostic value of Aβ imaging, and the role of Aβ pathology in disease generation. However, the editorial by Moghbel and colleagues brings into question the very feasibility of imaging Aβ in the brains of living humans [1]. Many of the issues raised in the editorial have been extensively researched and discussed in various scientific venues and publications over the past decade. However, it may be worthwhile to communicate these findings to a larger community, including scientists not